Edward Green1, Luke Hunt2, J C Gareth Ross3, Nina Marie Nissen3, Tanya Curran4, Anjna Badhan5, Katherine A Sutherland6, Jade Richards7, James S Lee8, Samuel H Allen9, Steven Laird10, Mandy Blackman11, Ian Collacott12, Paul A Parker13, Andrew Walbridge14, Rebecca Phillips3, Sia Jammie Sellu3, Agnes Dama3, Alpha Karim Sheriff3, Joseph Zombo3, Doris Ngegba3, Alieh H Wurie15, Francesco Checchi3, Timothy J Brooks16. 1. Tropical and Infectious Diseases Unit, Royal Liverpool University Hospital, Liverpool, UK. Electronic address: edwardgreen@doctors.org.uk. 2. Liverpool School of Tropical Medicine, Liverpool, UK. 3. Save the Children, London, UK. 4. Regional Virus Laboratory, Royal Victoria Hospital, Belfast, UK. 5. Antiviral Unit, Public Health England, London, UK. 6. University College London, London, UK. 7. Public Health England Laboratories, Freetown, Sierra Leone. 8. University of Alberta, Edmonton, AB, Canada. 9. University Hospital Crosshouse, Kilmarnock, UK. 10. Worcestershire Royal Hospital, Worcester, UK. 11. Kettering General Hospital, Kettering, UK. 12. Virology Laboratory, Aberdeen Royal Infirmary, Aberdeen, UK. 13. Portsmouth Hospitals NHS Trust, Portsmouth, UK. 14. Dorset County Hospital, Dorchester, UK. 15. Sierra Leone Ministry of Health, Freetown, Sierra Leone. 16. Rare and Imported Pathogens, Public Health England, Porton Down, UK.
Abstract
BACKGROUND: In survivors of Ebola virus disease, clinical sequelae including uveitis, arthralgia, and fatigue are common and necessitate systematic follow-up. However, the infection risk to health-care providers is poorly defined. Here we report Ebola virus RT-PCR data for body site and fluid samples from a large cohort of Ebola virus survivors at clinic follow-up. METHODS: In this cross-sectional cohort study, consecutive survivors of Ebola virus disease attending Kerry Town survivor clinic (Freetown, Sierra Leone), who had been discharged from the Kerry Town Ebola treatment unit, were invited to participate. We collected and tested axillary, blood, conjunctival, forehead, mouth, rectal, semen, urine, and vaginal specimens for presence of Ebola virus using RT-PCR. We regarded samples to be positive for Ebola virus disease if the cycle threshold was 40 or lower. We collected demographic data from survivors of their age, sex, time since discharge from the treatment unit, and length of acute admission in the Ebola treatment unit using anonymised standard forms. FINDINGS: Between April 2, and June 16, 2015, of 151 survivors of Ebola virus disease invited to participate, 112 (74%) provided consent. The median age of participants was 21·5 years (IQR 14-31·5) with 34 (30%) participants younger than 16 years. 50 (45%) of 112 participants were male. We tested a total of 555 specimens: 103 from the axilla, 93 from blood, 92 from conjunctiva, 54 from forehead, 105 from mouth, 17 from the rectum, one from semen, 69 from urine, and 21 from the vagina. The median time from Ebola treatment unit discharge to specimen collection was 142 days (IQR 127-159). 15 participants had a total of 74 swabs taken less than 100 days from discharge. The semen sample from one participant tested positive for Ebola virus at 114 days after discharge from the treatment unit; specimens taken from the axilla, blood, conjunctiva, forehead, mouth, rectum, and urine of the same participant tested negative. All specimens from the other 111 participants tested negative. INTERPRETATION: Patients recovering from Ebola virus disease who do not meet the case definition for acute disease pose a low infection risk to health-care providers 6 weeks after clearance of viraemia. Personal protective equipment after this time might be limited to standard barrier precautions, unless contact with fluids from sanctuary sites is envisaged. FUNDING: Save the Children International, Public Health England.
BACKGROUND: In survivors of Ebola virus disease, clinical sequelae including uveitis, arthralgia, and fatigue are common and necessitate systematic follow-up. However, the infection risk to health-care providers is poorly defined. Here we report Ebola virus RT-PCR data for body site and fluid samples from a large cohort of Ebola virus survivors at clinic follow-up. METHODS: In this cross-sectional cohort study, consecutive survivors of Ebola virus disease attending Kerry Town survivor clinic (Freetown, Sierra Leone), who had been discharged from the Kerry Town Ebola treatment unit, were invited to participate. We collected and tested axillary, blood, conjunctival, forehead, mouth, rectal, semen, urine, and vaginal specimens for presence of Ebola virus using RT-PCR. We regarded samples to be positive for Ebola virus disease if the cycle threshold was 40 or lower. We collected demographic data from survivors of their age, sex, time since discharge from the treatment unit, and length of acute admission in the Ebola treatment unit using anonymised standard forms. FINDINGS: Between April 2, and June 16, 2015, of 151 survivors of Ebola virus disease invited to participate, 112 (74%) provided consent. The median age of participants was 21·5 years (IQR 14-31·5) with 34 (30%) participants younger than 16 years. 50 (45%) of 112 participants were male. We tested a total of 555 specimens: 103 from the axilla, 93 from blood, 92 from conjunctiva, 54 from forehead, 105 from mouth, 17 from the rectum, one from semen, 69 from urine, and 21 from the vagina. The median time from Ebola treatment unit discharge to specimen collection was 142 days (IQR 127-159). 15 participants had a total of 74 swabs taken less than 100 days from discharge. The semen sample from one participant tested positive for Ebola virus at 114 days after discharge from the treatment unit; specimens taken from the axilla, blood, conjunctiva, forehead, mouth, rectum, and urine of the same participant tested negative. All specimens from the other 111 participants tested negative. INTERPRETATION:Patients recovering from Ebola virus disease who do not meet the case definition for acute disease pose a low infection risk to health-care providers 6 weeks after clearance of viraemia. Personal protective equipment after this time might be limited to standard barrier precautions, unless contact with fluids from sanctuary sites is envisaged. FUNDING: Save the Children International, Public Health England.
Authors: Mable Chan; Frederick W Holtsberg; Hong Vu; Katie A Howell; Anders Leung; Evelyn Van der Hart; Paul H Walz; M Javad Aman; Shantha Kodihalli; Darwyn Kobasa Journal: J Infect Dis Date: 2018-11-22 Impact factor: 5.226
Authors: Pauline Vetter; William A Fischer; Manuel Schibler; Michael Jacobs; Daniel G Bausch; Laurent Kaiser Journal: J Infect Dis Date: 2016-07-20 Impact factor: 5.226
Authors: Amy James Loftis; Saturday Quellie; Kelly Chason; Emmanuel Sumo; Mason Toukolon; Yonnie Otieno; Heinzfried Ellerbrok; Marcia M Hobbs; David Hoover; Karine Dube; David A Wohl; William A Fischer Journal: J Infect Dis Date: 2017-02-01 Impact factor: 5.226
Authors: Kevin Wing; Shefali Oza; Catherine Houlihan; Judith R Glynn; Sharon Irvine; Clare E Warrell; Andrew J H Simpson; Sabah Boufkhed; Alieu Sesay; Lahai Vandi; Sahr Charles Sebba; Pranav Shetty; Rachael Cummings; Francesco Checchi; Catherine R McGowan Journal: PLoS One Date: 2018-12-27 Impact factor: 3.240
Authors: William J Liu; Foday R Sesay; Antoine Coursier; Barbara Knust; Jaclyn E Marrinan; Shannon Whitmer; Suzanna L R McDonald; Philippe Gaillard; Yang Liu; Qiudong Su; Yong Zhang; Ian Crozier; Archchun Ariyarajah; Marylin Carino; Thomas Massaquoi; Nathalie Broutet; Wenbo Xu; Guizhen Wu; Ute Ströher; George F Gao; Pierre Formenty; Foday Sahr; Gibrilla F Deen Journal: Open Forum Infect Dis Date: 2019-02-26 Impact factor: 3.835